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Abstract
Preeclampsia is the main cause of maternal mortality and is associated
with a five-fold increase in perinatal mortality in developing coun-
tries. In spite of this, the etiology of preeclampsia is unknown. The
present article analyzes the contradictory results of the use of calcium
supplementation in the prevention of preeclampsia, and tries to give an
explanation of these results. The proposal of an integrative model to
explain the clinical manifestations of preeclampsia is discussed. In
this proposal we suggest that preeclampsia is caused by nutritional,
environmental and genetic factors that lead to the creation of an
imbalance between the free radicals nitric oxide, superoxide and
peroxynitrate in the vascular endothelium. The adequate interpreta-
tion of this model would allow us to understand that the best way of
preventing preeclampsia is the establishment of an adequate prenatal
control system involving adequate antioxidant vitamin and mineral
supplementation, adequate diagnosis and early treatment of asympto-
matic urinary and vaginal infections. The role of infection in the
genesis of preeclampsia needs to be studied in depth because it may
involve a fundamental change in the prevention and treatment of
preeclampsia.
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Introduction
Preeclampsia is a frequent disease with
an incidence of 5 to 7% among the general
population; however, geographic, social, eco-
nomic and racial differences are responsible
for an incidence that is up to three times
higher in some populations (1). In Colombia,
it is the main cause of maternal mortality
with up to 42% of maternal deaths being
attributed to this disorder (2). Preeclampsia
is associated with a five-fold increase in
perinatal mortality and its socioeconomic
impact on developing countries is huge, even
more so if we consider that in Colombia
maternal mortality is ten times higher than in
the United States (3).
In spite of its importance for public
health, the etiology of preeclampsia is un-
known. We believe that it is a complex disor-
der caused by a series of nutritional, environ-
mental and genetic factors that lead to the
creation of an imbalance between the free
radicals nitric oxide (NO), superoxide (O2-)
and peroxynitrate in the vascular endothe-
lium (4).
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Calcium supplementation and
preeclampsia: from epidemiological
and nutritional observations to
clinical trials and meta-analysis
Earlier observations considered nutri-
tional aspects to be an important risk factor
for preeclampsia. It was suggested that pro-
tein-calorie undernutrition may have an im-
portant role in the etiology of preeclampsia
(5). However, more recently a negative cor-
relation between calcium intake and the inci-
dence of preeclampsia was proposed. BelizÆn
and Villar (6) confirmed this initial associa-
tion among the Mayan Indians in Guate-
mala. Moreover, they observed that in coun-
tries such as Colombia and India, where the
mean calcium intake was between 250 and
300 mg per day, the incidence of eclampsia
was high (1.6 and 12.0 per 1000 live births,
respectively).
These observations were the initial sup-
port of our earlier clinical trials carried out to
determine the role of calcium supplementa-
tion in Andean pregnant women (7-10), a
population with a low calcium intake (11).
Our studies, conducted on 408 Ecuador-
ian pregnant women, suggested a beneficial
effect of calcium supplementation in pre-
venting preeclampsia (Table 1) and showed
that calcium deficiency plays an important
role in the pathogenesis of preeclampsia.
These results led other researchers to de-
velop large controlled trials around the world
to confirm the beneficial effects of calcium
supplementation in preventing preeclampsia
(12-18). All of these studies confirmed our
results; however, most of them did not have
enough statistical power to reach a definitive
conclusion. In contrast, the Calcium for Pre-
eclampsia Prevention (CPEP) trial, that in-
cluded more than 4000 North American
women, showed that calcium supplementa-
tion did not have any beneficial effect in
preventing preeclampsia among healthy nul-
liparous women (relative risk (RR): 0.94;
95% confidence interval (CI): 0.76-1.16)
(19).
Because of these contradictory results,
several authors have performed different
meta-analyses during the last few years (20-
23). These studies have found calcium to be
highly effective in preventing preeclampsia
with an overall odds ratio (OR) of 0.38; 95%
CI: 0.22-0.65 (23). Nevertheless, the real
value of meta-analysis in assessing the effi-
cacy of clinical interventions remains con-
troversial (24). In the case of trials with
calcium supplementation included in these
meta-analyses, the procedures were hetero-
geneous in several aspects: different doses
of calcium supplementation (450 mg to 2 g
per day), different starting times, different
durations of supplementation, and different
definitions of preeclampsia and pregnancy-
induced hypertension. These arguments have
been used by some authors to limit the im-
pact of the conclusions of meta-analysis,
especially when one considers that the only
large controlled trial did not show any ben-
eficial effect of calcium supplementation
(19).
However, the CPEP (19) has been the
target of several criticisms, mainly due to its
Table 1. Effect of calcium supplementation on the outcomes of Ecuadorian pregnant
women.
Parameter Group with Group without
supplementation  supplementation
Non-selected pregnanciesa N = 49 N = 43
Duration of pregnancy (weeks) 39.3 ± 1.8 38.7 ± 1.7
Birth weight (g) 3097 ± 276 2832 ± 318
Pregnancy-induced hypertension (N) 2 (14%)* 12 (27.9%)
High-risk pregnanciesb N = 22 N = 34
Duration of pregnancy (weeks) 39.2 ± 1.2** 37.4 ± 2.3
Birth weight (g) 2936 ± 396 2685 ± 427
Pregnancy-induced hypertension (N) 3 (14%)* 24 (71%)
Teenage pregnanciesc N = 125 N = 135
Duration of pregnancy (weeks) 39.6 ± 0.4 38.7 ± 0.3
Birth weight (g) 2907 ± 183 2797 ± 104
Preeclampsia (N) 4 (3.2%)* 21 (15.5%)
Data are reported as means ± SD. *P<0.001 and **P<0.01.
a,b,cData from Refs. 8, 9 and 10, respectively.
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limitation in applying its results to other
populations. While in the trials involving
populations with a low calcium intake cal-
cium supplementation was an intervention
to avoid a nutritional problem, in the CPEP
study calcium administration was a pharma-
cological intervention in women with a nor-
mal calcium intake (mean baseline intake
per day: 1130 mg). Moreover, other method-
ological criticisms are that the organoleptic
characteristics of placebo and calcium were
not completely similar, so that the supple-
ment was distributed to the patients in a dark
jar; but the more important criticism was
that, on average, the women studied took
only 64% of the supplement and only 20% of
them used more than 90% of the adminis-
tered dose.
These discrepancies indicate the impor-
tant aspects of the complex interaction be-
tween nutrients and supplements in different
populations. For instance, in our studies we
consistently found (10,11) a high phosphate
intake, even higher than the recommenda-
tions of the World Health Organization, pro-
vided by vegetables, especially tuberculous
and leguminous ones which are the base of
the diet of Andean women of low income.
This is important because intestinal calcium
absorption is decreased by the presence of
phosphate and vegetable fiber (25), a situa-
tion that could be particularly relevant to the
understanding of the contradictory results of
calcium supplementation.
The study Dietary Approaches to Stop
Hypertension (26) carried out on the North
American population showed that a diet rich
in fruit and vegetables, calcium supplements
(800 mg/day derived from dairy products)
and reduced fat intake decreased blood pres-
sure (systolic pressure by 5.5 mmHg and
diastolic pressure by 3.0 mmHg on average)
in relation to a typical North American diet
with or without fruits and vegetables, but
without the extra calcium. Interestingly, the
urinary calcium excretion of the subjects
consuming the typical North American diet
was similar to that of the subjects with fruit,
vegetable and calcium supplementation.
However, it was higher than that of subjects
consuming extra fruit and vegetables but
without calcium supplement. This result
could be explained by the concept that cal-
cium was bound to the added fiber intro-
duced in the diet, thus affecting its intestinal
absorption, a situation that could be im-
proved by the additional calcium intake.
The decreased calcium absorption in the
group that did not take the mineral supple-
ment abolished the beneficial effect of veg-
etable fiber in reducing blood pressure. Un-
fortunately, in the CPEP study, Levine et al.
(19) did not report the intake of other nutri-
ents, so that it was not possible to find out if
the absence of effect of calcium supplemen-
tation was due to different interactions with
other nutrients in the diet. In view of the
heterogeneity of the results included in the
meta-analysis and on the basis of the impor-
tance of calcium levels, a stratified analysis
by baseline dietary calcium intake (mean
calcium intake in the population <900 or
>900 mg/day) was conducted by Villar and
BelizÆn (23). The risk of preeclampsia was
considerably reduced in the six trials con-
ducted on populations with a low calcium
diet (typical relative risk (TRR): 0.32; 95%
CI: 0.21-0.49) but was not reduced as much
in women consuming adequate calcium di-
ets (TRR: 0.86; 95% CI: 0.71-1.05). Based
on these results, the authors suggested both
that calcium supplementation in women with
a low calcium diet is a promising preventive
strategy for preeclampsia and that this strat-
egy should be evaluated in a large controlled
trial conducted on a population with low
calcium intake (23).
Furthermore, a new meta-analysis re-
cently reported that calcium supplementa-
tion was associated with a reduction in the
risk of preeclampsia (RR: 0.70; 95% CI:
0.58-0.83) mainly for those with a low base-
line calcium intake (RR: 0.32; 95% CI: 0.21-
0.49). Thus, calcium supplementation ap-
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pears to be beneficial for women of popula-
tions with a low baseline calcium intake
(27).
Benefits of calcium supplementation
The mechanisms that lead to preeclamp-
sia are unknown. However, the hemody-
namic changes present during pregnancy,
such as increased cardiac output, decreased
systemic vascular resistance, increased blood
volume and increased renal flow and glo-
merular filtration (28), led us to think that
NO, a vasoactive substance produced by
vascular endothelium from the amino acid
L-arginine by the action of the enzyme endo-
thelial NO synthase, was responsible for
these hemodynamic changes (29). We sug-
gested that dietary calcium supplementation
reduces the frequency of preeclampsia by
maintaining the serum calcium ion level
which plays a crucial role in the production
of endothelial NO, the increased generation
of which maintains the vasodilation that is
characteristic of normal pregnancy (30). This
could explain the results obtained in the
clinical trials, in which we demonstrated that
calcium supplementation for women with a
low baseline calcium intake was associated
with an increase in serum calcium ion con-
centrations (7). Moreover, the decreased lev-
els of serum calcium ion observed in our
preeclamptic women were associated with
lower concentrations of cGMP, the effector
of NO actions (31).
Thus, we and others found that during
normal pregnancy the production of NO,
evaluated by plasma nitrite and nitrate lev-
els, was increased (32), as also was the activ-
ity of NO, evaluated by cGMP concentration
(31-33). The cause could be the increased
activity of NO synthase, probably related to
higher shear stress (34) or the physiological
increase of estrogens during pregnancy (35).
Nevertheless, the same did not occur with
preeclampsia, where we showed that the
plasma levels of nitrites and nitrates were
similar or increased compared with normal
pregnancies (31,32), but the urine and plasma
concentrations of cGMP were decreased (31).
These contradictory results were confirmed
by other authors (36,37). Moreover, diver-
gent results have been obtained by different
groups, a fact possibly due to different meth-
ods used to quantify nitrites and nitrates and
reflecting differences in the populations stud-
ied and in the intake of nitrates. Although
plasma concentration of nitrites and nitrates
may be high in preeclamptic women, the low
concentration of cGMP may be due to in-
creased NO inactivation, which might result
from excessive production of O2- (32,38).
This situation had already been demonstrated
in other cardiovascular diseases (39). In sup-
port of this proposal we found increased
levels of antibodies against oxidized LDL, a
marker of oxidative stress, in women with
preeclampsia (32). Similar results have been
reported by others using different markers of
oxidative stress (38,40).
The role of oxidative stress in preeclamp-
sia is also supported by the observation that
supplementation with vitamin antioxidants
during pregnancy decreases the incidence of
preeclampsia (41). At present there is good
evidence supporting the proposal of increased
oxidative stress in preeclampsia. For instance,
nitrotyrosine residues which are a marker of
peroxynitrate formation, a product of the
reaction between NO and O2-, are found in
placental vessels of preeclamptic and dia-
betic pregnancies, indicating increased oxi-
dative stress (42). Peroxynitrate causes dys-
function of placental vessels and alters the
normal increase in blood flow, thus leading
to damage to the fetus (42).
Factors that affect the production of
nitric oxide and superoxide
Healthy vascular endothelium provides a
tonic dilator tone and prevents the adhesion
of white cells and platelets to the vessel wall
(29). These actions are mediated by the pro-
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duction of NO and prostacyclin. Blockade of
NO synthesis reproduces many of the car-
diovascular changes of preeclampsia in ani-
mals (43). For example, acute blockade of
endothelial NO generation causes constric-
tion of resistance vessels, hypertension, al-
tered platelet reactivity, and adhesion of white
cells to the endothelium. Chronic blockade,
which promotes neointima formation, re-
sults in renal damage evidenced by protein-
uria. Inhibiting NO generation also worsens
endotoxin-induced glomerular thrombosis in
pregnant rats (44). Thus, endothelial dys-
function is likely to trigger white cell activa-
tion and a sequence of events that lead to
further endothelial damage.
Recently, it was proposed that acute in-
fections and the resulting inflammation might
impair the function of vascular endothelium
(45). Hingorani et al. (46) studied healthy
volunteers vaccinated with typhoid vaccine
who presented an inflammatory response
and cytokinemia. Eight hours after vaccina-
tion, forearm blood flow response to local
intra-arterial infusion of bradykinin was al-
most abolished and endothelium flow-de-
pendent dilatation of the brachial artery was
also reduced. In our population we have
observed that C-reactive protein is an inde-
pendent risk factor for essential hyperten-
sion (47).
The production and release of reactive
oxygen intermediates in endothelial cells,
such as O2- and hydrogen peroxide, are in-
duced by TNF-a, IL-1 and IL-6 via the acti-
vation of NAD(P)H oxidase (48).
Evidence for systemic inflammation
in preeclampsia
Proinflammatory cytokines appear to be
involved in cellular events that establish and
maintain pregnancy (49); however, their role
has not yet been well defined. The fetal
allograft, through activation of the maternal
immune system, may induce the secretion of
cytokines by maternal immunocompetent
cells. In healthy pregnant women, TNF-a is
thought to modulate the growth and invasion
of trophoblasts in maternal spiral arteries
(50). In keeping with a role for cytokines in
normal pregnancy, we have recently found
that circulating levels of TNF-a, C-reactive
protein, and IL-6 were elevated in healthy
pregnant Andean women in Quito during the
third trimester (51).
Abnormal cytokine responses in the
mother and fetus may be involved in the
pathogenesis of preeclampsia. Circulating
levels of TNF-a (50) were elevated in women
who developed preeclampsia in the third
trimester when compared with plasma con-
centrations in normotensive women matched
for gestational age. Recently, several inves-
tigators (52-54) have reported that serum
concentrations of IL-2, IL-6 and TNF-a and
its soluble receptor sTNFp55 were signifi-
cantly higher in the first and second trimes-
ter among pregnant women who subsequently
developed preeclampsia compared to those
in the control group. These results suggest
that the perturbation of immune regulation
may precede the clinical manifestation of
preeclampsia.
We had observed that pregnant women in
the Andes, who have a high risk for pre-
eclampsia and chronic subclinical infection,
have increased levels of C-reactive protein
during the third trimester (51). These results
are consistent with the proposal that pre-
eclampsia is associated with a greater in-
flammatory response than observed in nor-
mal pregnancy (53). Furthermore, the levels
of IL-6 and TNF-a that we detected in the
Ecuadorian women studied were significantly
higher than those reported for European and
North American women (52,54) and in-
creased more substantially during both nor-
mal pregnancy and preeclampsia. Whether
these differences are related to genetic (in-
flammatory response and L-arginine:NO
pathway) and/or environmental factors (e.g.,
infection) remains to be determined.
We have also shown that preeclamptic
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women had higher leukocyte counts and in-
creased total number of neutrophils com-
pared to a matched normal pregnancy group
(51). These results provide further evidence
of enhanced inflammation in preeclampsia,
as recently reported by other groups in dif-
ferent populations (53,54). These studies
were undertaken in women with established
preeclampsia; therefore, it cannot be deter-
mined whether the increase in C-reactive
protein and proinflammatory cytokines was
a cause or a consequence of the disease
(51,54).
Is infection a major risk factor for
preeclampsia?
A growing body of evidence links infec-
tion and inflammatory processes with pre-
eclampsia. Hill et al. (55) found that the
incidence of asymptomatic bacteriuria was
higher in pregnant women with preeclamp-
sia (19%) than in normal gravidas (3 to 6%).
Hsu and Witter (56) reported that the inci-
dence of urinary tract infection in preeclamp-
tic pregnant women was higher than in nor-
motensive pregnant women. Urinary tract
infection was shown to be a strong risk fac-
tor for eclampsia, with OR of 4.23 (95% CI:
1.05-5.09) in a multivariate logistic regres-
sion analysis of characteristics associated
with eclampsia (57). These findings have
been confirmed recently by Mittendorf et al.
(58), who observed that urinary tract infec-
tion during pregnancy was associated with
nearly a two-fold increased risk for pre-
eclampsia. Moreover, primiparas who had a
urinary tract infection were five times more
likely (OR 5.3; 95% CI: 2.9-9.7) to develop
preeclampsia than primiparas who did not
have urinary tract infection during pregnancy.
The role of infection in the pathogenesis
of preeclampsia is particularly relevant in
developing countries, where the high inci-
dence of chronic subclinical infection may
contribute to the high incidence of preeclamp-
sia. Recently we have developed a program
of biopsychosocial risk assessment that adds
to standard prenatal care (59). This method
allows to identify pregnant women at high
risk of preeclampsia, helps to define nutri-
tional interventions like supplementation of
calcium and linoleic acid to prevent pre-
eclampsia, and to screen and treat asympto-
matic urinary and cervical infections, thus
reducing maternal and perinatal morbidity
and mortality. The innovative aspects were
the early identification and corrections of
risk factors for preeclampsia and preterm
delivery in all pregnant women receiving
prenatal care at 129 health centers and hos-
pitals of the public health service in the
western part of Colombia.
A total of 15,354 pregnant women be-
tween 14-20 weeks of gestational age were
included, 1,443 (9.4%) of whom were at
high risk of developing preeclampsia and
received nutritional supplementation during
pregnancy with 450 mg/day of linoleic acid
and 1.5 g/day of elemental calcium started at
25-32 gestational weeks. Asymptomatic bac-
teriuria was identified in 1,766 (11.5%) preg-
nant women and vaginal infections and bac-
terial vaginosis were detected in 2,150
women (14.0%). Both bacteriuria and vagi-
nal infections were identified in 783 (5.1%)
pregnant women. Physicians prescribed oral
antibiotics for 7-10 days according to the
type of organism grown in culture, with a
compliance of 88%. Moreover, the tests were
repeated following completion of the treat-
ment to assess its efficacy and treatment was
repeated when necessary. These interven-
tions led to a 64% decrease in the incidence
of preeclampsia, from 5.1% observed during
the five years preceding the program to 1.8%
during the program (59).
We believe that this dramatic reduction
in the incidence of preeclampsia was due to
the early identification of risk factors, the
administration of nutritional supplements and
principally the treatment of asymptomatic
infections. In fact, only 1,443 women re-
ceived nutritional supplementation but 3,133
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pregnant women received oral antibiotics
for 7-10 days to treat infection. It is highly
tempting to speculate that the early treat-
ment of asymptomatic infections may have
been the predominant factor that contributed
to the improvement of pregnancy outcomes.
Unfortunately, the results described here are
from an open population-based program.
Consequently, it is not possible to make a
definitive statement that infection is the ma-
jor risk factor for preeclampsia. However,
based on these results, we have proposed
that chronic subclinical infections may in-
crease maternal cytokines to levels high
enough to affect vascular endothelial func-
tion in individuals with a predisposition to
subsequent development of preeclampsia
(59).
Conclusions
After 20 years of medical research on the
etiology and the mechanisms that lead to
preeclampsia, we believe that this disease
results from the interaction between eco-
nomic, psychosocial, nutritional, environ-
mental and genetic factors that lead to a
common alteration, i.e., an imbalance in the
production of free radicals, NO, O2- and
peroxynitrate (60). In Figure 1 we present an
integrative model where all the known risk
factors and the new ones are listed together
to explain the clinical manifestations of pre-
eclampsia.
An adequate interpretation of this model
would allow us to understand that the best
way to prevent preeclampsia in a universal
and effective manner is the establishment of
an adequate prenatal control system, whose
procedures should contain an adequate vita-
min (A, C and E) and mineral (calcium and
iron) supplementation. In addition, adequate
prenatal control would allow physicians to
diagnose and promptly treat asymptomatic
urinary and vaginal infections. Finally, the
role that infection and inflammation may
play in the imbalance of free radicals that
leads to preeclampsia needs to be studied in
depth because it may involve a fundamental
change in the prevention and treatment of
preeclampsia.
Decreased levels of serum ionic calcium
and increased levels of cholesterol,
triglycerides, LDL, and oxo-LDL
Socioeconomic situation
Nutritional
status
Health
services
Sanitary
infrastructure
Social
insecurity
Deficient calcium and
antioxidant vitamin
intake and high
fat intake
Inadequate
prenatal control
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delivery
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subclinical chronic
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NAD(P)H oxidase
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Figure 1. Interaction between different social, economic, nutritional and environmental
factors that contribute to creating an imbalance between nitric oxide/superoxide (NO/O2-)
that leads to the subsequent development of preeclampsia. CRP, C-reactive protein; PGI2,
prostaglandin I2; TXA2, thromboxane A2.
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